Small biotechs access stock market; bubble concerns rise
This article was originally published in Scrip
Executive Summary
From initial public offerings to reverse stock splits and mergers, the public markets are the place to be for biotechnology companies as small and mid-sized firms take advantage of rising investor interest in the drug development business.